[1] Luduena, R. F. A hypothesis on the origin and evolution of tubulin. Int. Rev. Cell Mol. Biol. 2013, 302, 41–185.
[2] Dumontet, C.; Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9, 790–803.
[3] Parker, A. L.; Teo, W. S.; Mccarroll, J. A.; Kavallaris, M. An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance. Int. J. Mol. Sci. 2017, 18, 1434.
[4] Issell, B. F.; Crooke, S. T. Maytansine. Cancer Treat. Rev. 1978, 5, 199–207.
[5] Li, L.; Jiang S.; Li, X.; Liu, Y.; Su, J.; Chen, J. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. Eur. J. Med. Chem. 2018, 151, 482–494.
[6] Coulup, S. K.; Georg, G. I. Revisiting microtubule targeting agents: alpha-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics. Bioorg. Med. Chem. Lett. 2019, 29, 1865–1873.
[7] Balkrishna, A.; Das, S. K.; Pokhrel, S.; Joshi, A.; Verma, S.; Sharma, V. K.; Sharma, V.; Sharma, N.; Joshi, C. S. Colchicine: Isolation, LC-MS QTof Screening, and Anticancer Activity Study of Gloriosa superba Seeds. Molecules 2019, 24, 2772.
[8] Goto, H.; Yano, S.; Zhang, H.; Matsumori, Y.; Ogawa, H.; Blakey, D. C.; Sone, S. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res. 2002, 62, 3711–3715.
[9] Combes, S.; Barbier, P.; Douillard, S.; McLeer-Florin, A.; Bourgarel-Rey, V.; Pierson, J. T.; Fedorov, A. Y.; Finet, J. P.; Boutonnat, J.; Peyrot, V. Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins. Part 2. J. Med. Chem. 2011, 54, 3153–3162.
[10] Kim, T. J.; Ravoori, M.; Landen, C. N.; Kamat, A. A.; Han, L, Y.; Lu, C.; Lin, Y. G.; Merritt, W. M.; Jennings, N.; Spannuth, W. A. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007, 67, 9337–9345.
[11] Hori, K.; Saito, S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Br. J. Cancer. 2004, 90, 549–553.
[12] Cortese, F.; Bhattacharyya, B.; Wolff, J. Podophyllotoxin as a probe for the colchicine binding site of tubulin. J. Biol. Chem. 1977, 252, 1134–1140.
[13] Verdier-Pinard, P.; Sitachitta, N.; Rossi, J. V.; Sackett, D. L.; Gerwick, W. H.; Hamel, E. Biosynthesis of Radiolabeled Curacin A and Its Rapid and Apparently Irreversible Binding to the Colchicine Site of Tubulin. Arch. Biochem. Biophys. 1999, 370, 51–58.
[14] Kim, D. Y.; Kim, K. H.; Kim, N. D.; Lee, K. Y.; Han, C. K.; Yoon, J. H.; Moon, S. K.; Lee, S. S.; Seong, B. L. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J. Med. Chem. 2006, 49, 5664.
[15] Risinger, A. L.; Westbrook, C. D.; Encinas, A.; Mulbaier, M.; Schultes, C. M.; Wawro, S.; Lewis, J. D.; Janssen, B.; Giles, F. J.; Mooberry, S. L. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2011, 336, 652–660.
[16] Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004, 64, 4621–4628.
[17] Beckers, T.; Reissmann, T.; Schmidt, M.; Burger, A. M.; Fiebig, H. H.; Vanhoefer, U.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Mahboobi, S. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res, 2002, 62, 3113–3119.
[18] Banerjee, A.; Luduena, R. F. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J. Biol. Chem.1992, 267,13335–13339.
[19] Singer, W. D.; Jordan, M. A.; Wilson, L.; Himes, R. H. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol. 1989, 36, 366–370.
[20] Lobert, S.; Vulevic, B.; Correia, J. J.; Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996, 35, 6806.
[21] Matesanz, R.; Barasoain, I.; Yang, C. G.; Wang, L.; Li, X.; Inés, C. d.; Coderch, C.; Gago, F.; Barbero, J. J.; Andreu, J. M.; Fang, W. S.; Díaz, J. F. Optimization of Taxane Binding to Microtubules: Binding Affinity Dissection and Incremental Construction of a High-Affinity Analog of Paclitaxel. Cell Chem. Biol. 2008, 15, 573–585.
[22] Cormier, A.; Marchand, M.; Ravelli, R. B. G.; Knossow, M.; Gigant, B. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep. 2008, 9, 1101–1106.
[23] Chao, M. W.; Lai, M. J.; Liou, J. P.; Chang, Y. L.; Wang, J. C.; Pan, S. L.; Teng, C. M. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J. Hematol. Oncol. 2015, 8, 82.
[24] Bai, R. L.; Paull, K. D.; Herald, C. L.; Malspeis, L.; Pettit, G. R.; Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 1991, 266, 15882–15889.
[25] Jordan, M. A.; Kamath, K.; Manna, T.; Okouneva, T.; Miller, H. P.; Davis, C.; Littlefield, B. A.; Wilson, L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005, 4, 1086–1095.
[26] Kuznetsov, G.; TenDyke, K.; Towle, M. J.; Cheng, H. S.; Liu, J. K.; Marsh, J. P.; Schiller, S. E. R.; Spyvee, M. R.; Yang, H.; Seletsky, B. M.; Shaffer, C. J.; Marceau, V.; Yao, Y.; Suh, E.M.; Campagna, S.; Fang, F. G.; Kowalczyk, J.; Lottlefield, B. A. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol. Cancer Ther. 2009, 8, 2852–2860.
[27] Aherne, G. W.; Hardcastle, A.; Valenti, M.; Bryant, A.; Rogers, P.; Pettit, G. R.; Srirangam, J. K.; Kelland, L. R. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother. Pharmacol. 1996, 38, 225–232.
[28] Prota, A. E.; Bargsten, K.; Diaz, J. F.; Marsh, M.; Cuevas, C.; Liniger, M.; Neuhaus, C.; Andreu, J. M.; Altmann, K. H.; Steinmetz, M. O. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 13817–13821.
[29] Navarrete, K. R.; Jimenez, V. A. Interdimeric Curvature in Tubulin-Tubulin Complexes Delineates the Microtubule- Destabilizing Properties of Plocabulin. J. Chem. Inf. Model. 2020, 60, 4076–4084.
[30] Kondoh, M.; Usui, T.; Kobayashi, S.; Tsuchiya, K.; Nishikawa, K.; Nishikiori, T.; Mayumi, T.; Osada, H. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett. 1998, 126, 29–32.
[31] Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 655–657.
[32] Mielgo, A.; Torres, V. A.; Clair, K.; Barbero, S.; Stupack, D. G. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 2009, 28, 3551–3562.
[33] Rothermel, J.; Wartmann, M.; Chen, T.; Hohneker, J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin. Oncol. 2003, 30, 51–55.
[34] ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochem. 1996, 35, 243–250.
[35] Mooberry, S. L.; Tien, G.; Hernandez, A. H.; Plubrukarn, A.; Davidson, B. S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res. 1999, 59, 653–660.
[36] Hood, K. A.; West, L. M.; Rouwé, B.; Northcote, P. T.; Berridge, M. V.; Wakefield, S. J.; Miller, J. H. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. Cancer Res. 2002, 62, 3356–3360.
[37] Zúñiga, M. A.; Alderete, J. B.; Jaña, G. A.; Fernandez, P. A.; Ramos, M. J.; Jiménez, V. A. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents. Chem. Biol. Drug Des. 2018, 91, 1042–1055. |